VGX-1027
CAS No. 6501-72-0
VGX-1027 ( VGX-1027 )
产品货号. M15470 CAS No. 6501-72-0
VGX-1027(GIT27) 是一种异恶唑化合物,具有多种免疫调节特性;减少纯化的小鼠巨噬细胞分泌 IL-1β、TNF-α 和 IL-10。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥425 | 有现货 |
|
| 10MG | ¥617 | 有现货 |
|
| 25MG | ¥1190 | 有现货 |
|
| 50MG | ¥2130 | 有现货 |
|
| 100MG | ¥3321 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ¥416 | 有现货 |
|
生物学信息
-
产品名称VGX-1027
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述VGX-1027(GIT27) 是一种异恶唑化合物,具有多种免疫调节特性;减少纯化的小鼠巨噬细胞分泌 IL-1β、TNF-α 和 IL-10。
-
产品描述VGX-1027(GIT27) is an isoxazole compound that exhibits various immunomodulatory properties; reduce the secretion of IL-1beta, TNF-alpha and IL-10 from purified murine macrophages.(In Vitro):VGX-1027 (37.5, 75, 150, 300 μM; for 24 h) does not affect the viability of tumor cells,including the three malignant rodent cell lines (mouse fibrosarcoma L929, rat astrocytoma C6, and mouse melanoma B16) and the four human cell lines (adenocarcinoma HeLa, breast carcinoma BT20, colon carcinoma LS174, and glioblastoma U251).(In Vivo):VGX-1027 (10, 20 mg/kg of i.p. for 12 day or 100 mg/kg of p.o. for 11 day) successfully counteractes the development of destructive insulitis and hyperglycemia.VGX-1027 (25?mg/kg; ip; single dose) counteracts the uveitis-inducing effect of LPS in eight-week-old male Lewis rats (180-220?g).
-
体外实验VGX-1027 (37.5, 75, 150, 300 μM; for 24 h) does not affect the viability of tumor cells,including the three malignant rodent cell lines (mouse fibrosarcoma L929, rat astrocytoma C6, and mouse melanoma B16) and the four human cell lines (adenocarcinoma HeLa, breast carcinoma BT20, colon carcinoma LS174, and glioblastoma U251).
-
体内实验VGX-1027 (10, 20 mg/kg of i.p. for 12 day or 100 mg/kg of p.o. for 11 day) successfully counteractes the development of destructive insulitis and hyperglycemia. VGX-1027 (25?mg/kg; ip; single dose) counteracts the uveitis-inducing effect of LPS in eight-week-old male Lewis rats (180-220?g). Animal Model:Adult male mice, at 6 to 8 weeks of age with 25 to 30 g Dosage:10, 20 mg/kg for i.p. or 100 mg/kg for p.o.Administration:IP daily for 12 consecutive day or PO daily for 11 consecutive day Result:Successfully counteracted the development of destructive insulitis and hyperglycemia to the mice made diabetic with multiple low doses of Streptozotocin.
-
同义词VGX-1027
-
通路Apoptosis
-
靶点IL Receptor
-
受体IL-10| IL-1β| TNF-α
-
研究领域Inflammation/Immunology
-
适应症——
化学信息
-
CAS Number6501-72-0
-
分子量205.21
-
分子式C11H11NO3
-
纯度>98% (HPLC)
-
溶解度Ethanol: 41 mg/mL (199.79 mM); DMSO: 41 mg/mL (199.79 mM)
-
SMILESO=C(O)CC1CC(C2=CC=CC=C2)=NO1
-
化学全称2-(3-phenyl-4,5-dihydroisoxazol-5-yl)acetic acid
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Stosic-Grujicic S, et al. J Pharmacol Exp Ther. 2007, 320(3), 1038-1049.
产品手册
关联产品
-
Benralizumab
Benralizumab (MEDI-563) (MEDI-563 (anti-IL5RA ); BIW-8405 (anti-IL5RA )) 是一种白介素 5 受体 α(IL-5Rα) 定向的溶细胞单克隆抗体,通过增强抗体依赖性细胞介导的细胞毒性诱导嗜酸性粒细胞直接,快速和几乎完全耗尽。Benralizumab 可用于严重的嗜酸性哮喘研究。
-
Secukinumab
Secukinumab 是一种完全人源化的单克隆抗 IL-17A 抗体,也是同类产品中第一个获得美国食品和药物管理局批准用于治疗中度至重度斑块状银屑病的抗体。
-
Ixekizumab
Ixekizumab 是一种人源化 IgG4 单克隆抗体,可选择性结合和中和白细胞介素 IL-17A (KD<3 pM)。Ixekizumab 直接阻断IL-17A与IL-17RA的结合,但不与其他IL-17家族成员结合。Ixekizumab 用于中重度斑块型银屑病的研究。
021-51111890
购物车()
sales@molnova.cn

